The novel class of GLP-1 receptor agonist and GIP co-agonist medications, including tirzepatide, semaglutide, and the newly introduced retatrutide, provide promising progress in the control. While all https://motscpeptide140977.dsiblogger.com/76944011/tirzepatide-a-thorough-review